In 2025, we took several important steps to maximize LINZESS, advance aproglutide, and deliver sustained profits and cash flows to strengthen our financial position and position the company for ...
Q4 2025 net price was negatively impacted by the timing of gross-to-net rebate reserves where units dispensed exceeded units sold to wholesalers. Management expects a more than 30% increase in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results